Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Naltrexone/Bupropion ER (Contrave): Newly Approved Treatment Option for Chronic Weight Management in Obese Adults.

Literature DB >> 26957883

Naltrexone/Bupropion ER (Contrave): Newly Approved Treatment Option for Chronic Weight Management in Obese Adults.

Matthew M Sherman, Sinziana Ungureanu, Jose A Rey.

Abstract

Naltrexone/bupropion ER (Contrave): newly approved treatment option for chronic weight management in obese adults.

Entities: Chemical Disease

Year: 2016 PMID： 26957883 PMCID： PMC4771085

Source DB: PubMed Journal: P T ISSN： 1052-1372

20 in total

1. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation.

Authors: Miia Turpeinen; Ari Tolonen; Jouko Uusitalo; Jorma Jalonen; Olavi Pelkonen; Kari Laine
Journal: Clin Pharmacol Ther Date: 2005-06 Impact factor: 6.875

2. Annual medical spending attributable to obesity: payer-and service-specific estimates.

Authors: Eric A Finkelstein; Justin G Trogdon; Joel W Cohen; William Dietz
Journal: Health Aff (Millwood) Date: 2009-07-27 Impact factor: 6.301

3. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Authors: Frank L Greenway; Ken Fujioka; Raymond A Plodkowski; Sunder Mudaliar; Maria Guttadauria; Janelle Erickson; Dennis D Kim; Eduardo Dunayevich
Journal: Lancet Date: 2010-07-29 Impact factor: 79.321

Review 4. ACS chemical neuroscience molecule spotlight on contrave.

Authors: Susan L Mercer
Journal: ACS Chem Neurosci Date: 2011-09-21 Impact factor: 4.418

5. Differential expression and sensitivity of presynaptic and postsynaptic opioid receptors regulating hypothalamic proopiomelanocortin neurons.

Authors: Reagan L Pennock; Shane T Hentges
Journal: J Neurosci Date: 2011-01-05 Impact factor: 6.167

6. Altered expression of hypothalamic neuropeptide mRNAs in food-restricted and food-deprived rats.

Authors: L S Brady; M A Smith; P W Gold; M Herkenham
Journal: Neuroendocrinology Date: 1990-11 Impact factor: 4.914

Review 7. Regulation of thermogenesis by the central melanocortin system.

Authors: Wei Fan; Adriana Voss-Andreae; Wei-Hua Cao; Shaun F Morrison
Journal: Peptides Date: 2005-10 Impact factor: 3.750

8. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.

Authors: Thomas A Wadden; John P Foreyt; Gary D Foster; James O Hill; Samuel Klein; Patrick M O'Neil; Michael G Perri; F Xavier Pi-Sunyer; Cheryl L Rock; Janelle S Erickson; Holly N Maier; Dennis D Kim; Eduardo Dunayevich
Journal: Obesity (Silver Spring) Date: 2010-06-17 Impact factor: 5.002

9. Rational design of a combination medication for the treatment of obesity.

Authors: Frank L Greenway; M J Whitehouse; Maria Guttadauria; James W Anderson; Richard L Atkinson; Ken Fujioka; Kishore M Gadde; Alok K Gupta; Patrick O'Neil; Donald Schumacher; Diane Smith; Eduardo Dunayevich; Gary D Tollefson; Eckard Weber; Michael A Cowley
Journal: Obesity (Silver Spring) Date: 2008-11-06 Impact factor: 5.002

10. Demonstration of in vivo synthesis of pro-opiomelanocortin-, beta-endorphin-, and alpha-melanotropin-like species in the adult rat brain.

Authors: A S Liotta; J P Advis; J E Krause; J F McKelvy; D T Krieger
Journal: J Neurosci Date: 1984-04 Impact factor: 6.167

10 in total

Review 1. Naltrexone-bupropion (Mysimba) in management of obesity: A systematic review and meta-analysis of unpublished clinical study reports.

Authors: Igho J Onakpoya; Joseph J Lee; Kamal R Mahtani; Jeffrey K Aronson; Carl J Heneghan
Journal: Br J Clin Pharmacol Date: 2020-02-04 Impact factor: 4.335

2. Sex differences in the effect of bupropion and naltrexone combination on alcohol drinking in mice.

Authors: Yan Zhou; Francesco Leri; Malcolm J Low; Mary Jeanne Kreek
Journal: Pharmacol Biochem Behav Date: 2019-04-13 Impact factor: 3.533

3. An open-label trial on the efficacy and tolerability of naltrexone/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder.

Authors: Elvira Anna Carbone; Mariarita Caroleo; Marianna Rania; Giuseppina Calabrò; Filippo Antonio Staltari; Renato de Filippis; Matteo Aloi; Francesca Condoleo; Franco Arturi; Cristina Segura-Garcia
Journal: Eat Weight Disord Date: 2020-04-30 Impact factor: 4.652

Review 4. Converging vulnerability factors for compulsive food and drug use.

Authors: Katherine M Serafine; Laura E O'Dell; Eric P Zorrilla
Journal: Neuropharmacology Date: 2021-04-20 Impact factor: 5.273

Review 5. The incretin/glucagon system as a target for pharmacotherapy of obesity.

Authors: Stefano Del Prato; Baptist Gallwitz; Jens Juul Holst; Juris J Meier
Journal: Obes Rev Date: 2021-10-28 Impact factor: 10.867

6. Weight-loss response to naltrexone/bupropion is modulated by the Taq1A genetic variant near DRD2 (rs1800497): A pilot study.

Authors: Jamie A Mullally; Wendy K Chung; Charles A LeDuc; Tirissa J Reid; Gerardo Febres; Steven Holleran; Rajasekhar Ramakrishnan; Judith Korner
Journal: Diabetes Obes Metab Date: 2021-01-08 Impact factor: 6.408

7. Mesolimbic opioid-dopamine interaction is disrupted in obesity but recovered by weight loss following bariatric surgery.

Authors: Henry K Karlsson; Lauri Tuominen; Semi Helin; Paulina Salminen; Pirjo Nuutila; Lauri Nummenmaa
Journal: Transl Psychiatry Date: 2021-05-01 Impact factor: 6.222